ClinicalTrials.gg
RecruitingNCT07226999Updated Oct 8, 2026

Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer

A Phase 2/3 interventional study of PF-08634404 and Atezolizumab in Small Cell Lung Cancer (SCLC), sponsored by Pfizer. Recruiting at 82 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Pfizer · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Updated Sep 28, 2026Site recruiting status changed1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
550
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Small Cell Lung Carcinoma by Pfizer — 4 open to participants now, 5 under way, 1 of them phase 3. Small Cell Lung Carcinoma · Pfizer.

Planned enrollment
2nd of 12
550 · median 227
Started
2025
the only one that year
Phase 2/3
Only one
of the 12
Registered
11th of 12
by date

Among the 12 studies in Small Cell Lung Carcinoma by Pfizer, this one is the 2nd largest by planned enrollment, is the only one that started in 2025, is the only one in phase 2/3, and was the 11th registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

4 of the 12 studies in Small Cell Lung Carcinoma by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Small Cell Lung Carcinoma by Pfizer, or all of them as a file.
02

Study summary

This study is being done to learn more about a new medicine called PF-08634404 and how well it works when given with chemotherapy to adults with extensive-stage small cell lung cancer (ES-SCLC), a fast-growing type of lung cancer that has spread widely in the body.

To join the study, participants must meet the following conditions:

  • Be 18 years or older.
  • Have extensive-stage small cell lung cancer confirmed by lab tests.
  • Have not received chemotherapy or radiation for this type of lung cancer.
  • Be in good physical condition and have healthy organs based on medical tests.

The study has two parts:

  • In the first part, researchers will check how safe the study medicine is and how well people tolerate it when given with chemotherapy.
  • In the second part, they will compare study medicine plus chemotherapy to another approved treatment (atezolizumab plus chemotherapy) to see which works better.

Participants will receive the treatment through IV infusions (medicine given directly into a vein). The treatment will be given in repeated time periods called cycles. Some participants will continue receiving the study medicine alone after the initial treatment.

03

Conditions studied

  • Small Cell Lung Cancer (SCLC)

Keywords

  • small cell lung cancer
  • extensive stage small cell lung cancer
  • first-line
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed extensive-stage small cell lung cancer (ES-SCLC).
  • Participants have not received systemic therapy (chemotherapy, radiotherapy, chemoradiation) for ES-SCLC.
  • Treatment-free for at least 6 months since last chemo/radiotherapy, among those treated (with curative intent) with prior chemo/radiotherapy for limited-stage SCLC
  • Have at least one as the targeted lesion based on V1.1.
  • performance status of 0 or 1.
  • Adequate organ function

Exclusion criteria

Exclusion Criteria:

  • known active CNS lesions, including brainstem, meningeal, or spinal cord or compression
  • risk of hemorrhage or fistula
  • history of another within 3 years
  • active diseases requiring systemic treatment within the past 2 years
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
550 participants (estimated)

Study arms

  • Experimental
    Phase 2 Single arm

    Participants will receive PF-08634404 in combination with chemotherapy

    Drug: PF-08634404 · Drug: Chemotherapy

  • Experimental
    Phase 3 Experimental Arm

    Participants will receive PF-08634404 in combination with chemotherapy

    Drug: PF-08634404 · Drug: Chemotherapy

  • Active comparator
    Phase3 Control Arm

    Participants will receive atezolizumab in combination with chemotherapy

    Biological: Atezolizumab · Drug: Chemotherapy

Interventions

  • Concentrate for solution for infusion

  • BiologicalAtezolizumab

    Injection for intravenous use

  • DrugChemotherapy

    Injection for intravenous use

06

What researchers measure

Primary outcomes

  1. Phase 2: Confirmed Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST 1.1] based on the investigator's assessment

    Defined as the proportion of participants in whom a confirmed complete response (CR) or partial response (PR) is observed as best overall response. ORR using RECIST v1.1 as assessed by investigator.

    Time frame: Up to approximately 2 years after completion of study treatment of last study participant

  2. Phase 2: Number of participants with treatment-emergent adverse events

    Adverse Events (AEs) as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study intervention.

    Time frame: Up to 90 days after the last dose of treatment

  3. Phase 3: Overall Survival (OS)

    OS is defined as the time from the date of randomization to the date of death due to any cause. OS is secondary outcome measure in Phase 2 portion of the study.

    Time frame: Up to approximately 2 years after completion of study treatment of last study participant

Secondary outcomes

  1. Duration of Response (DOR) as assessed by Investigator based on RECIST v1.1

    DOR is defined as the time from the first documentation of objective response (CR or PR) to the date of first documentation of progressive disease (PD) or death due to any cause.

    Time frame: Up to approximately 2 years after completion of study treatment of last study participant

  2. Progression Free Survival (PFS) as assessed by investigator based on RECIST v1.1

    PFS is defined as the time from the date of randomization to the date of first documented disease progression, per RECIST v1.1, or death to any cause, whichever occurs first

    Time frame: Up to approximately 2 years after completion of study treatment of last study participant

  3. Number of participants with Laboratory abnormalities

    Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing.

    Time frame: Up to 90 days after the last dose of treatment

  4. Phase 2: Number of Participants who Experience a Dose-Limiting Toxicity (DLT)

    DLT (any of the prespecified AEs that are attributable to study treatment(s), excluding toxicities clearly due to underlying disease or extraneous causes) rate estimated based on data from DLT-evaluable participants during the DLT evaluation period.

    Time frame: Up to 90 days after the last dose of treatment

  5. Pharmacokinetics: Serum concentrations of PF-08634404

    Time frame: Up to 37 days after the last dose of treatment

  6. Incidence of antidrug antibody against PF-08634404

    Time frame: Up to 37 days after the last dose of treatment

  7. Phase 2: Overall Survival

    Overall survival defined as the time from the date of randomization to the date of death due to any cause.

    Time frame: Up to approximately 2 years after completion of study treatment of last study participant

  8. Phase 3: PFS using RECIST v1.1 as assessed by blinded independent central review (BICR)

    Progression Free Survival (PFS) is defined as the time from the date of randomization to the date of the first documentation of objective PD assessed by BICR per RECIST v1.1, or death due to any cause, whichever occurs first.

    Time frame: Up to approximately 2 years after completion of study treatment of last study participant

  9. Phase 3: Confirmed ORR using RECIST v1.1 as assessed by BICR

    ORR is defined as the proportion of participants in the analysis population having a best overall response (BOR) of confirmed CR or confirmed PR according to RECIST v1.1 as assessed by BICR.

    Time frame: Up to approximately 2 years after completion of study treatment of last study participant

  10. Phase 3: DOR using RECIST v1.1 as assessed by BICR

    The time from the first documentation of objective response (CR or PR that is subsequently confirmed) to the date of the first documentation of PD as determined by BICR assessment per RECIST v1.1, or death due to any cause, whichever occurs first.

    Time frame: Up to approximately 2 years after completion of study treatment of last study participant

  11. Phase 3: Mean scores and Change from baseline in the global health status/quality of life (QoL), function, and symptom scores on the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)

    The EORTC QLQ-C30 is a questionnaire for quantitative measure of health-related quality of life pertinent to participants with a broad range of cancers who are participating in international clinical trials.

    Time frame: Up to approximately 2 years after completion of study treatment of last study participant

  12. Phase 3: Mean scores and Change from Baseline on the EORTC Quality of Life Cancer Questionnaire - Lung Cancer 13 (EORTC QLQ-LC13)

    EORTC QLQ-LC13 is a lung cancer specific module that serves as an additional 13 item questionnaire to the general EORTC cancer questionnaire, the EORTC QLQ-C30.

    Time frame: Up to approximately 2 years after completion of study treatment of last study participant

  13. Phase 3: Time to definitive deterioration (TTdD) in the global health status/QoL, function, and symptom scores on the EORTC QLQ-C30

    TTdD is defined as the time from date of randomization to first onset of Patient Reported Outcome (PRO) deterioration without subsequent recovery.

    Time frame: Up to approximately 2 years after completion of study treatment of last study participant

  14. Phase 3: TTdD in the dyspnea, cough, and chest pain scores on the EORTC QLQ-LC13

    TTdD is defined as the time from date of randomization to first onset of Patient Reported Outcome (PRO) deterioration without subsequent recovery.

    Time frame: Up to approximately 2 years after completion of study treatment of last study participant

07

Study locations

82 of 82 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for Jun 2030, 54 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2025
First posted
Nov 12, 2025
StartActual
Dec 9, 2025
Primary completionEst.
Jun 14, 2030
CompletionEst.
Mar 11, 2034
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site removed. 17 sites changed recruiting status (17 now recruiting)
Show 17 sites
  • University Hospitals Cleveland Medical Center · Cleveland, United StatesNot yet recruiting→Recruiting
  • Texas Oncology - Northeast Texas · Allen, United StatesNot yet recruiting→Recruiting
  • Texas Oncology - DFW · Arlington, United StatesNot yet recruiting→Recruiting
  • Texas Oncology - DFW · Bedford, United StatesNot yet recruiting→Recruiting
  • Texas Oncology - DFW · Dallas, United StatesNot yet recruiting→Recruiting
  • Texas Oncology - Northeast Texas · Denison, United StatesNot yet recruiting→Recruiting
  • Texas Oncology - Northeast Texas · Denton, United StatesNot yet recruiting→Recruiting
  • Texas Oncology - Northeast Texas · Flower Mound, United StatesNot yet recruiting→Recruiting
  • Texas Oncology - DFW · Fort Worth, United StatesNot yet recruiting→Recruiting
  • Texas Oncology - DFW · Grapevine, United StatesNot yet recruiting→Recruiting
  • Texas Oncology - Northeast Texas · Lewisville, United StatesNot yet recruiting→Recruiting
  • Texas Oncology - Northeast Texas · Longview, United StatesNot yet recruiting→Recruiting
  • Texas Oncology - Northeast Texas · McKinney, United StatesNot yet recruiting→Recruiting
  • Texas Oncology - Northeast Texas · Palestine, United StatesNot yet recruiting→Recruiting
  • Texas Oncology - Northeast Texas · Paris, United StatesNot yet recruiting→Recruiting
  • Texas Oncology - DFW · Plano, United StatesNot yet recruiting→Recruiting
  • Texas Oncology - Northeast Texas · Tyler, United StatesNot yet recruiting→Recruiting
Show 1 removed
  • US Oncology Investigational Products Center (IPC) · Irving, United States
Sep 28, 2026
Show all 2 updates
  1. Oct 8, 2026
    Minor edits only
    + 1 other change: verification date
  2. Sep 28, 2026
    1 site removed. 23 sites changed recruiting status (23 now recruiting)
    Show 23 sites
    • University Hospitals Cleveland Medical Center · Cleveland, United StatesNot yet recruiting→Recruiting
    • Texas Oncology - Northeast Texas · Allen, United StatesNot yet recruiting→Recruiting
    • Texas Oncology - DFW · Arlington, United StatesNot yet recruiting→Recruiting
    • Texas Oncology - DFW · Arlington, United StatesNot yet recruiting→Recruiting
    • Texas Oncology - DFW · Bedford, United StatesNot yet recruiting→Recruiting
    • Texas Oncology - DFW · Dallas, United StatesNot yet recruiting→Recruiting
    • Texas Oncology - DFW · Dallas, United StatesNot yet recruiting→Recruiting
    • Texas Oncology - DFW · Dallas, United StatesNot yet recruiting→Recruiting
    • Texas Oncology - DFW · Dallas, United StatesNot yet recruiting→Recruiting
    • Texas Oncology - DFW · Dallas, United StatesNot yet recruiting→Recruiting
    • Texas Oncology - Northeast Texas · Denison, United StatesNot yet recruiting→Recruiting
    • Texas Oncology - Northeast Texas · Denton, United StatesNot yet recruiting→Recruiting
    • Texas Oncology - Northeast Texas · Flower Mound, United StatesNot yet recruiting→Recruiting
    • Texas Oncology - DFW · Fort Worth, United StatesNot yet recruiting→Recruiting
    • Texas Oncology - DFW · Grapevine, United StatesNot yet recruiting→Recruiting
    • Texas Oncology - Northeast Texas · Lewisville, United StatesNot yet recruiting→Recruiting
    • Texas Oncology - Northeast Texas · Longview, United StatesNot yet recruiting→Recruiting
    • Texas Oncology - Northeast Texas · McKinney, United StatesNot yet recruiting→Recruiting
    • Texas Oncology - Northeast Texas · Palestine, United StatesNot yet recruiting→Recruiting
    • Texas Oncology - Northeast Texas · Paris, United StatesNot yet recruiting→Recruiting
    • Texas Oncology - DFW · Plano, United StatesNot yet recruiting→Recruiting
    • Texas Oncology - DFW · Plano, United StatesNot yet recruiting→Recruiting
    • Texas Oncology - Northeast Texas · Tyler, United StatesNot yet recruiting→Recruiting
    Show 1 removed
    • US Oncology Investigational Products Center (IPC) · Irving, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07226999
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Nov 12, 2025
Start date
Dec 9, 2025
Primary completion
Jun 14, 2030 (estimated)
Completion
Mar 11, 2034 (estimated)
Last update
Oct 8, 2026

Study contacts

Pfizer CT.gov Call Center
Contact
ClinicalTrials.gov_Inquiries@pfizer.com
1-800-718-1021
Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-PD-1/Anti-VEGF Bispecific Antibody PF-08634404

Start the discussion